Lipid Nanocarriers for Systemic STING Agonist Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing STING agonists for cancer treatment have limited systemic activity due to poor stability, necessitating local delivery and restricting their utility.
Innovation Solution
Development of lipid-based and albumin-based nanocarriers for STING agonists to enhance delivery and systemic activity, combined with immune modulatory drugs and nucleic acid delivery for cancer, autoimmune, and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first generation STING agonists are used for cancer treatment, then safety is demonstrated, but systemic activity is limited due to poor stability requiring local delivery
Solution Approach 1:
The patent introduces lipid-based and albumin-based nanocarriers as intermediary delivery systems that transport STING agonists throughout the body. These nanocarriers act as mediators between the stable, safe STING agonist molecules and the target tissues, enabling systemic distribution while maintaining the agonist's stability and safety profile. The nanocarriers protect the agonists from degradation and facilitate their delivery to various organs and tissues.
Solution Approach 2:
The patent modifies the physical and chemical parameters of STING agonist delivery by transitioning from direct administration to nancarrier-mediated delivery. This parameter change enables the agonists to achieve systemic activity while maintaining their stability and safety characteristics. The nanocarriers alter the pharmacokinetic parameters, allowing for improved bioavailability and distribution throughout the body.
2Ease of operation
If STING agonists are administered with poor stability, then local delivery is required, but utility is limited
Solution Approach 1:
The patent develops nancarrier systems that can deliver STING agonists to multiple different tissues and organs, making the delivery system universal rather than tissue-specific. The same nancarrier platform can be adapted for various indications including cancer, autoimmune diseases, and infectious diseases, thereby enhancing utility while maintaining ease of administration.
Solution Approach 2:
The nanocarriers serve as intermediary vehicles that enable the STING agonists to reach target tissues systemically. These intermediaries protect the agonists from degradation during circulation and facilitate their delivery to various organs, transforming a locally-limited therapy into a systemically-active treatment with broad utility.
Data Source
AI summary
The present disclosure provides STING agonists, and compositions, formulations, and methods for treating diseases or disorders (e.g., cancer, inflammatory diseases, autoimmune diseases, and infectious diseases) with the STING agonists or compositions thereof.